Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
turletricin
- Development stage
- Phase 3
- Lead developer
- Elion Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Turletricin (EL219) is a next-generation polyene antifungal and a derivative of amphotericin B, developed by Elion Therapeutics. It is engineered to selectively target fungal ergosterol while avoiding human cholesterol, a design intended to significantly reduce the nephrotoxicity typically associated with traditional amphotericin B. The drug maintains broad-spectrum activity against various fungal pathogens. It has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for the treatment of invasive aspergillosis and early antifungal therapy. Clinical development includes Phase 2 trials for invasive mould infections and cryptococcal meningitis, with a once-weekly dosing regimen.
- Brand names
- SF001SF-001SF 001
- Other names
- Sfu-AM2-19ASfu-AM-2-19ASfu-AM 2-19A
02
Targets
Ergosterol
Beyond the preview
Go deeper on turletricin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on turletricin.